These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33024029)

  • 1. Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer.
    Kong Y; Zhang Y; Mao F; Zhang Z; Li Z; Wang R; Liu J; Liu X
    Mol Cancer Ther; 2020 Dec; 19(12):2490-2501. PubMed ID: 33024029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer.
    Shankar E; Franco D; Iqbal O; Moreton S; Kanwal R; Gupta S
    Toxicol Appl Pharmacol; 2020 Oct; 404():115200. PubMed ID: 32805266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
    J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.
    Wu C; Jin X; Yang J; Yang Y; He Y; Ding L; Pan Y; Chen S; Jiang J; Huang H
    Oncotarget; 2016 Jan; 7(3):3440-52. PubMed ID: 26657505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer.
    Liu Q; Wang G; Li Q; Jiang W; Kim JS; Wang R; Zhu S; Wang X; Yan L; Yi Y; Zhang L; Meng Q; Li C; Zhao D; Qiao Y; Li Y; Gursel DB; Chinnaiyan AM; Chen K; Cao Q
    Int J Cancer; 2019 Jul; 145(2):415-426. PubMed ID: 30628724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src.
    Shi XB; Ma AH; Xue L; Li M; Nguyen HG; Yang JC; Tepper CG; Gandour-Edwards R; Evans CP; Kung HJ; deVere White RW
    Cancer Res; 2015 Dec; 75(24):5309-17. PubMed ID: 26573802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms.
    Koh CM; Iwata T; Zheng Q; Bethel C; Yegnasubramanian S; De Marzo AM
    Oncotarget; 2011 Sep; 2(9):669-83. PubMed ID: 21941025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
    Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.
    Zeng D; Liu M; Pan J
    Oncotarget; 2017 Jan; 8(2):3396-3411. PubMed ID: 27926488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of EZH2 and activation of ERRγ synergistically suppresses gastric cancer by inhibiting FOXM1 signaling pathway.
    Huang B; Mu P; Yu Y; Zhu W; Jiang T; Deng R; Feng G; Wen J; Zhu X; Deng Y
    Gastric Cancer; 2021 Jan; 24(1):72-84. PubMed ID: 32529327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer.
    Zhou L; Mudianto T; Ma X; Riley R; Uppaluri R
    Clin Cancer Res; 2020 Jan; 26(1):290-300. PubMed ID: 31562203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The phytochemical 3,3'-diindolylmethane decreases expression of AR-controlled DNA damage repair genes through repressive chromatin modifications and is associated with DNA damage in prostate cancer cells.
    Palomera-Sanchez Z; Watson GW; Wong CP; Beaver LM; Williams DE; Dashwood RH; Ho E
    J Nutr Biochem; 2017 Sep; 47():113-119. PubMed ID: 28582660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a.
    Uchiyama N; Tanaka Y; Kawamoto T
    Eur J Pharmacol; 2017 Oct; 812():138-146. PubMed ID: 28705714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
    Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
    J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.
    Kleb B; Estécio MR; Zhang J; Tzelepi V; Chung W; Jelinek J; Navone NM; Tahir S; Marquez VE; Issa JP; Maity S; Aparicio A
    Epigenetics; 2016 Mar; 11(3):184-93. PubMed ID: 26890396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine.
    Barazeghi E; Hellman P; Norlén O; Westin G; Stålberg P
    Sci Rep; 2021 Nov; 11(1):22733. PubMed ID: 34815475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer.
    Takayama K; Suzuki T; Tsutsumi S; Fujimura T; Urano T; Takahashi S; Homma Y; Aburatani H; Inoue S
    Oncotarget; 2015 Feb; 6(4):2263-76. PubMed ID: 25537508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-26a-5p restoration
    Zhang W; Nie Q; Zhang X; Huang L; Pang G; Chu J; Yuan X
    Expert Opin Ther Targets; 2023; 27(12):1285-1297. PubMed ID: 38155599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
    Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
    Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer.
    Li X; Gera L; Zhang S; Chen Y; Lou L; Wilson LM; Xie ZR; Sautto G; Liu D; Danaher A; Mamouni K; Yang Y; Du Y; Fu H; Kucuk O; Osunkoya AO; Zhou J; Wu D
    Theranostics; 2021; 11(14):6873-6890. PubMed ID: 34093859
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.